Cross-reactive humoral and CD4
CD4+ T cell
SARS-CoV-2
antibody
breakthrough infections
hybrid immunity
natural infection
vaccination
variants
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
06
2023
accepted:
07
07
2023
medline:
15
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
The SARS CoV-2 antibody and CD4
Identifiants
pubmed: 37575243
doi: 10.3389/fimmu.2023.1241038
pmc: PMC10413264
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241038Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00065
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260541
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Martel, Cuervo-Rojas, Ángel, Ariza, González, Ramírez-Santana, Acosta-Ampudia, Murcia-Soriano, Montoya, Cardozo-Romero, Valderrama-Beltrán, Cepeda, Castellanos, Gómez-Restrepo, Perdomo-Celis, Gazquez, Dickson, Brien, Mateus, Grifoni, Sette, Weiskopf and Franco.
Déclaration de conflit d'intérêts
AS is or has been a consultant for Arcturus, Cell Carta/Caprion, Oxford Immunotech, Repertoire and Pfizer, Moderna, AstrZeneca, Flowpharma, Qiagen, EmerVac and Gritstone. La Jolla Institute has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Lancet Microbe. 2022 Jan;3(1):e21-e31
pubmed: 34778853
Front Immunol. 2022 Dec 21;13:1102384
pubmed: 36618393
Commun Med (Lond). 2023 Jul 13;3(1):97
pubmed: 37443390
BMJ. 2021 Dec 15;375:e068848
pubmed: 34911691
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Nat Immunol. 2022 May;23(5):781-790
pubmed: 35383307
Sci Adv. 2021 Mar 5;7(10):
pubmed: 33674317
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
N Engl J Med. 2021 Aug 12;385(7):664-666
pubmed: 34233096
Commun Med (Lond). 2022 Apr 5;2:36
pubmed: 35603265
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
Vaccines (Basel). 2022 Jan 24;10(2):
pubmed: 35214639
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Vaccines (Basel). 2022 Dec 14;10(12):
pubmed: 36560554
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Front Immunol. 2022 May 31;13:863554
pubmed: 35711445
Front Immunol. 2022 May 02;13:879036
pubmed: 35585980
Emerg Infect Dis. 2022 Aug;28(8):1708-1712
pubmed: 35830278
Cell Host Microbe. 2022 Mar 9;30(3):388-399.e3
pubmed: 35172129
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
N Engl J Med. 2021 Dec 16;385(25):2397-2399
pubmed: 34731554
Cell Rep. 2022 May 3;39(5):110754
pubmed: 35477025
Curr Microbiol. 2022 Feb 12;79(4):96
pubmed: 35150319
J Med Virol. 2022 Aug;94(8):3988-3991
pubmed: 35474317
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Nat Commun. 2021 Jun 30;12(1):4043
pubmed: 34193870
PLoS One. 2022 Sep 19;17(9):e0274484
pubmed: 36121816
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
Sci Transl Med. 2023 Mar 22;15(688):eadg2783
pubmed: 36947596
Nat Immunol. 2020 Dec;21(12):1506-1516
pubmed: 33028979
Science. 2021 Oct 22;374(6566):eabj9853
pubmed: 34519540
Med Microbiol Immunol. 2023 Feb;212(1):25-34
pubmed: 36370196
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Lancet Microbe. 2022 May;3(5):e348-e356
pubmed: 35345417
Sci Transl Med. 2023 Mar 15;15(687):eade0550
pubmed: 36921035
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Int J Infect Dis. 2021 Aug;109:85-89
pubmed: 34161801
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Front Immunol. 2022 Apr 13;13:867716
pubmed: 35493512
Immunity. 2023 Apr 11;56(4):864-878.e4
pubmed: 36996809
Annu Rev Immunol. 2023 Apr 26;41:343-373
pubmed: 36750314
Cell Rep Med. 2023 Jan 17;4(1):100898
pubmed: 36584684
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Sci Transl Med. 2022 Aug 10;14(657):eabm4908
pubmed: 35579540
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nat Commun. 2021 Mar 29;12(1):1951
pubmed: 33782398